The primary objective is to investigate if abrupt withdrawal versus gradual withdrawal of pharmacotherapy (solifenacin and/or mirabegron) influences the risk of recurrence of incontinence.
Children aged 5-14 years diagnosed with urinary incontinence, treated with pharmacotherapy of solifenacin and/or mirabegron and ready for withdrawal will be randomized 1:1 to either abrupt or gradual withdrawal, according to the medical treatment that the child is receiving.

Start Date27 May 2024

Sponsor / Collaborator

University of Aarhus

IRCT20190618043934N25 / RecruitingPhase 3

Comparison of the therapeutic effects of posterior tibial nerve stimulation and the anticholinergic drug sulifenacin in patients with hyperactive bladder

Start Date20 Apr 2024

Sponsor / Collaborator

Mashhad University of Medical Sciences

NCT06024005 / CompletedNot ApplicableIIT

A Prospective Randomized Controlled Trial: Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Oral Solifenacin Treatments' Effects in Women Between 18-80 Years Old Who Have Overactive Bladder

Overactive bladder (OAB) syndrome is a symptom complex characterized by sudden urgency, frequent urination, nocturia, and urge incontinence without any identifiable organic cause, significantly impacting the quality of life. One of the most prominent symptoms is the urgency to urinate accompanied by a sudden sensation of bladder fullness.
There are various treatment options available for managing OAB, including conservative therapy, pharmacotherapy, and surgical management. High-level evidence supports solifenacin as the standard medical treatment for OAB, offering advantages such as not being affected by food intake, efficacy regardless of gender, and high bioavailability. However, it is known to cause discontinuation of treatment in many cases due to the occurrence of side effects. Posterior tibial nerve stimulation (PTNS) is a neuromodulation technique that has been internationally recognized and proven effective in the treatment of OAB, providing several advantages. It can be applied through two methods: percutaneous (PTNS) and transcutaneous (TTNS). PTNS is an invasive method that requires specialized equipment and a trained healthcare professional, which limits its routine use due to treatment costs.
In the literature, it is stated that in the treatment of OAB, alone or combined PTNS applications are superior to drug monotherapies, but there are limited studies on this subject. Therefore, the study aim was to compare the efficacy, side effects and quality of life of solifenacin and TTNS.

Start Date18 Apr 2023

Sponsor / Collaborator

Ege Universitesi

100 Clinical Results associated with Solifenacin Succinate

100 Translational Medicine associated with Solifenacin Succinate

100 Patents (Medical) associated with Solifenacin Succinate

142

Literatures (Medical) associated with Solifenacin Succinate

01 Jan 2024·Urology

Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities

Article

Author: Escobar, Christina M ; Dusetzina, Stacie B ; Shapiro, Katherine ; Brucker, Benjamin M

OBJECTIVE:

To report out-of-pocket costs associated with overactive bladder (OAB) medications among Medicare beneficiaries and the uninsured.

METHODS:

We performed a cross-sectional analysis of the Centers for Medicare & Medicaid Services Prescription Drug Plan Formulary Data (Q1-2022). FDA-approved medications for OAB were identified. We calculated out-of-pocket costs for Medicare beneficiaries in each Part D prescription benefit phase, average retail price, total yearly costs and discounted prices through cash-pay discount coupons (GoodRx) or online pharmacies like Mark Cuban Cost Plus Drug Company (MCCPDC). We also report plan utilization management requirements.

RESULTS:

We analyzed 5721 plan formularies for 18 medications. Mirabegron was the only beta-3 agonist (B3). Only Vesicare oral solution (14.3% of plans) and Mirabegron (0.1%) required prior authorization. Many plans required step therapy for selective generic anticholinergics (ACH) (12.4%-43.3%), while the B3 rarely required step therapy (0.6%). Monthly costs varied by coverage phase and averaged $59 for ACHs in the initial coverage phase ($14 in catastrophic; $72 in coverage gap). The monthly cost for the B3 averaged $47 in the initial coverage phase ($26 in catastrophic; $129 in coverage gap). The total yearly cost for generic ACHs ranged from $494 (oxybutynin IR) to $1452 (darifenacin) and the yearly cost for brand-name ACHs ranged from $1175 (Toviaz ER) to $2198 (Oxytrol). The total yearly cost for the B3 was $1283.

CONCLUSION:

We evaluated coverage, out-of-pocket costs, total yearly costs, and utilization management for OAB medications to make pricing more transparent. While selective medications may be "covered," coverage does not translate into affordable drug prices.

01 Jan 2024·Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

A preliminary study of the effects of an antimuscarinic agent on anxious behaviors and white matter microarchitecture in nonhuman primates

Article

Author: Riedel, Marissa K ; Brotman, Melissa A ; Kalin, Ned H ; Aggarwal, Nakul ; Tromp, Do P M ; Roseboom, Patrick H ; Oler, Jonathan A ; Elam, Victoria R

Myelination subserves efficient neuronal communication, and alterations in white matter (WM) microstructure have been implicated in numerous psychiatric disorders, including pathological anxiety. Recent work in rodents suggests that muscarinic antagonists may enhance myelination with behavioral benefits; however, the neural and behavioral effects of muscarinic antagonists have yet to be explored in non-human primates (NHP). Here, as a potentially translatable therapeutic strategy for human pathological anxiety, we present data from a first-in-primate study exploring the effects of the muscarinic receptor antagonist solifenacin on anxious behaviors and WM microstructure. 12 preadolescent rhesus macaques (6 vehicle control, 6 experimental; 8F, 4M) were included in a pre-test/post-test between-group study design. The experimental group received solifenacin succinate for ~60 days. Subjects underwent pre- and post-assessments of: 1) anxious temperament (AT)-related behaviors in the potentially threatening no-eye-contact (NEC) paradigm (30-min); and 2) WM and regional brain metabolism imaging metrics, including diffusion tensor imaging (DTI), quantitative relaxometry (QR), and FDG-PET. In relation to anxiety-related behaviors expressed during the NEC, significant Group (vehicle control vs. solifenacin) by Session (pre vs. post) interactions were found for freezing, cooing, and locomotion. Compared to vehicle controls, solifenacin-treated subjects exhibited effects consistent with reduced anxiety, specifically decreased freezing duration, increased locomotion duration, and increased cooing frequency. Furthermore, the Group-by-Session-by-Sex interaction indicated that these effects occurred predominantly in the males. Exploratory whole-brain voxelwise analyses of post-minus-pre differences in DTI, QR, and FDG-PET metrics revealed some solifenacin-related changes in WM microstructure and brain metabolism. These findings in NHPs support the further investigation of the utility of antimuscarinic agents in targeting WM microstructure as a means to treat pathological anxiety.

30 Dec 2023·Journal of chromatographic science

Expeditive Chromatographic Methods for Quantification of Solifenacin Succinate along with its Official Impurity as the Possible Acid Degradation Product

Article

Author: Eissa, Maya S ; Fayed, Ahmed S ; Hegazy, Maha A ; Kamel, Ebraam B

Abstract:

Two selective stability-indicating procedures were adopted for the quantification of Solifenacin succinate (SOL) along with its acid degradant, in its powder form or in pharmaceutical tablet. Under stress conditions, the acid degradation pathway of SOL was investigated, its official impurity (SOL imp-A) was obtained as the possible acid degradation product, also. A densitometric technique based on the separation of SOL from SOL imp-A employing HPTLC plates prelaminated with silica gel 60 F254 as the stationary phase and a developing solution containing methanol:chloroform:ammonia (8:1:1, v/v/v) and UV scanning of the developed bands at 220 nm. Linear regression analysis data for the calibration plot of SOL showed perfect linear relationships throughout the range of concentration 10–60 μg/band. A reversed phase C18 analytical column (4.6 × 250 mm, 5 μm) was also used to separate the mixture at a flow rate of 1 mL/min, using acetonitrile:0.05 M phosphate buffer (70:30, v/v) as the mobile phase and phosphoric acid to set pH = 3.5. Quantification was obtained at 220 nm using peak area and linear calibration curve across a concentration range of 10–70 μg/mL. The recommended procedures were applied to the existing dosage form, and they generated satisfactory results.

News (Medical) associated with Solifenacin Succinate

29 Jun 2022

·www.prnewswire.com

Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio

NEW YORK, June 29, 2022 /PRNewswire/ -- The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market growth across various regions. The interstitial cystitis drugs market size is expected to increase by USD 283.95 million, at a CAGR of 5.06% from 2020 to 2025. Technavio categorizes the interstitial cystitis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the interstitial cystitis drugs market during the forecast period. Technavio has announced its latest market research report titled Interstitial Cystitis Drugs Market by Type and Geography - Forecast and Analysis 2021-2025 For more highlights on the parent market analysis - Request a sample now! Market Dynamics Drivers: The high prevalence of interstitial cystitis is notably driving the interstitial cystitis drugs market growth Trends: Increasing awareness of interstitial cystitis is the key market trend driving the interstitial cystitis drugs market growth. Challenges: The major challenge impeding the interstitial cystitis drugs market growth is the lack of approved drugs. For detailed highlights on the market dynamics - Click Now! Segmentation Analysis By Type, the market is classified into oral therapy and intravesical therapy. The interstitial cystitis drugs market share growth by the oral therapy segment will be significant for revenue generation. Pentosan polysulfate sodium (ELMIRON) is the only approved oral medication to repair the lining of the bladder in people with interstitial cystitis (IC). ELMIRON builds and restores the protective coating of the bladder tissue. There are many off-label oral drugs in the interstitial cystitis drugs market that can reduce the signs and symptoms of the disease facilitating the growth of the segment during the forecast period. By Geography, the market is classified as North America, Europe, Asia, and ROW. 36% of the market's growth will originate from North America during the forecast period. The US is a key market for interstitial cystitis drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe. The increasing cases of interstitial cystitis and a rise in research funding will facilitate the interstitial cystitis drugs market growth in North America over the forecast period. Company Profiles The interstitial cystitis drugs market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The interstitial cystitis drugs market report provides complete insights on key vendors including Astellas Pharma Inc., Bayer AG, Johnson and Johnson Inc., Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Key Offerings: Perrigo Co. Plc - The company offers pain and sleep aids such as Ibuprofen. Pfizer Inc. - The company offers an interstitial cystitis drug named Toviaz. Seikagaku Corp. - The company is developing the interstitial cystitis and bladder pain syndrome drug SI-722. Sun Pharmaceutical Industries Ltd. - The company offers interstitial cystitis drugs such as Cystopen capsules Teva Pharmaceutical Industries Ltd. The company offers interstitial cystitis drugs such as VESIcare (solifenacin succinate) Tablets. To know about all major vendor offerings - Grab a sample now! Get ready to achieve excellent business outcomes from this exclusive Interstitial Cystitis Drugs Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as - What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe? What is the current trend taking place in the market space? Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market? What are market drivers, restraints, and challenges impacting demand & growth of the market? Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years? The competitive scenario provided in the Interstitial Cystitis Drugs Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, Make a strategic approach & boost your business goals with our Interstitial Cystitis Drugs Market Forecast Report - Buy Now! Related Reports: The uveitis drugs market share is expected to increase to USD 269.65 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%. The vitiligo therapeutics market share is expected to increase to USD 341.35 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.5%. Table of Content 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain analysis: Pharmaceuticals 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by Type 5.1 Market segments Exhibit 15: Type - Market share 2020-2025 (%) 5.2 Comparison by Type Exhibit 16: Comparison by Type 5.3 Oral therapy - Market size and forecast 2020-2025 Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million) Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%) 5.4 Intravesical therapy - Market size and forecast 2020-2025 Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million) Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%) 5.5 Market opportunity by Type Exhibit 21: Market opportunity by Type 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 24: Geographic comparison 7.3 North America - Market size and forecast 2020-2025 Exhibit 25: North America - Market size and forecast 2020-2025 ($ million) Exhibit 26: North America - Year-over-year growth 2020-2025 (%) 7.4 Europe - Market size and forecast 2020-2025 Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 28: Europe - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 30: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 32: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 33: Key leading countries 7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 36: Vendor landscape 9.3 Landscape disruption Exhibit 37: Landscape disruption Exhibit 38: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 39: Vendors covered 10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors 10.3 Astellas Pharma Inc. Exhibit 41: Astellas Pharma Inc. - Overview Exhibit 42: Astellas Pharma Inc. - Product and service Exhibit 43: Astellas Pharma Inc. - Key news Exhibit 44: Astellas Pharma Inc. - Key offerings 10.4 Bayer AG Exhibit 45: Bayer AG - Overview Exhibit 46: Bayer AG - Business segments Exhibit 47: Bayer AG - Key news Exhibit 48: Bayer AG - Key offerings Exhibit 49: Bayer AG - Segment focus 10.5 Johnson and Johnson Inc. Exhibit 50: Johnson and Johnson Inc. - Overview Exhibit 51: Johnson and Johnson Inc. - Business segments Exhibit 52: Johnson and Johnson Inc. - Key news Exhibit 53: Johnson and Johnson Inc. - Key offerings Exhibit 54: Johnson and Johnson Inc. - Segment focus 10.6 Novartis AG Exhibit 55: Novartis AG - Overview Exhibit 56: Novartis AG - Business segments Exhibit 57: Novartis AG - Key news Exhibit 58: Novartis AG - Key offerings Exhibit 59: Novartis AG - Segment focus 10.7 Perrigo Co. Plc Exhibit 60: Perrigo Co. Plc - Overview Exhibit 61: Perrigo Co. Plc - Business segments Exhibit 62: Perrigo Co. Plc - Key news Exhibit 63: Perrigo Co. Plc - Key offerings Exhibit 64: Perrigo Co. Plc - Segment focus 10.8 Pfizer Inc. 10.9 Seikagaku Corp. Exhibit 69: Seikagaku Corp. - Overview Exhibit 70: Seikagaku Corp. - Business segments Exhibit 71: Seikagaku Corp. - Key offerings Exhibit 72: Seikagaku Corp. - Segment focus 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 77: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Viatris Inc. Exhibit 81: Viatris Inc. - Overview Exhibit 82: Viatris Inc. - Business segments Exhibit 83: Viatris Inc. - Key offerings Exhibit 84: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 85: Currency conversion rates for US$ 11.3 Research methodology Exhibit 86: Research Methodology Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Information sources 11.4 List of abbreviations Exhibit 89: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

23 Jun 2017

·www.bioportfolio.com

Global and Chinese Solifenacin succinate Industry, 2017 Market Research Report [Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Solifenacin succinate Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Solifenacin succinate industry with a focus on the Chinese market. The report provides key statistics on the market status of the Solifenacin succinate manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 20122017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Solifenacin succinate industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 20172022 market development trends of Solifenacin succinate industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Solifenacin succinate Industry before evaluating its feasibility. Overall, the report provides an indepth insight of 20122022 global and Chinese Solifenacin succinate industry covering all important parameters. Any special requirements about this report, please let us know and we can provide custom report.

100 Deals associated with Solifenacin Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
D01269	Solifenacin Succinate	G04BD08	DB01591

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	US	Astellas Pharma US, Inc.	26 May 2020
Urinary Bladder, Overactive	JP	Astellas Pharma, Inc.	20 Apr 2006
Pollakisuria	US	Astellas Pharma US, Inc.	19 Nov 2004
Urinary Incontinence, Urge	US	Astellas Pharma US, Inc.	19 Nov 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Overactive bladder syndrome	Phase 3	US	Astellas Pharma, Inc.	01 Jun 2004
Urinary urgency	Phase 3	BE	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	CZ	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	EG	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	FR	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	DE	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	GR	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	HU	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	IT	Astellas Pharma, Inc.	01 Apr 2004
Urinary urgency	Phase 3	PL	Astellas Pharma, Inc.	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04090190 (CTgov)	Phase 4	Urinary Incontinence \| Urinary urgency \| Inflammation	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	jlxqdxtyqj(mmgwrbbzqq) = uszbpbsjga pgsxgxoysj (pkrxmpcdvn, eeaatromql - aoogjtgvly) View more	-	03 Oct 2022
NCT01565694 (CTgov)	Phase 3	Neurogenic detrusor overactivity	76	Solifenacin succinate	fassqmsghd(fzierrbkyy) = gcmkiiaxqh xooenfrbkc (zglwhxtieb, lhuugvjbol - aybttxuzpi) View more	-	06 May 2019
NCT02549196 (CTgov)	Phase 2	Dystocia \| Dementia due to Alzheimer's disease (disorder)	28	Donepezil+Solifenacin (Cohort 1)	snmviqbyoy(sdquplepby) = rkinclpggx xgbqsrddgq (pdonsehied, wiquorjnsi - tioopjxhel) View more	-	05 Mar 2019
				Donepezil+Solifenacin (Cohort 2)	snmviqbyoy(sdquplepby) = mribmlwfoz xgbqsrddgq (pdonsehied, zbhxmzigbv - bfqyffonje) View more
NCT02294396 (CTgov)	Phase 4	Urinary Bladder, Overactive	649	Mirabegron tablet+Solifenacin tablet (Mirabegron + Solifenacin)	qgsdltfkkf(okdiznzyzt) = cswetydeao hfpiusoqhi (tvhxfvbbli, zyrqifdbfq - fwwkkurnlk) View more	-	24 Dec 2018
				Mirabegron tablet+Propiverine tablet (Mirabegron + Propiverine)	qgsdltfkkf(okdiznzyzt) = vzynzhqccd hfpiusoqhi (tvhxfvbbli, suuvadzjix - zysokzcdjt) View more
NCT01981954 (CTgov)	Phase 3	Neurogenic detrusor overactivity	23	solifenacin succinate	wlxrozssnp(zzjcqvdzur) = yhbaxytxcd ohnafdwdfc (xndhiqvmbr, xtvdkggesb - rjbjcmcocw) View more	-	21 Jun 2018
NCT01972841 (CTgov)	Phase 3	Urinary Bladder, Overactive	3,527	placebo (Placebo)	ihscktyong(xtiqwmhaju) = koksxzlbqe geizucmfjc (yvriilpfyk, ogeuxofdgz - hdbdtzsqxz) View more	-	12 Jun 2018
				Mirabegron (Mirabegron 25 mg)	ihscktyong(xtiqwmhaju) = oatcedvntb geizucmfjc (yvriilpfyk, aefjempwsv - zyrdxeeppj) View more
NCT02045862 (SYNERGY II, CTgov)	Phase 3	Urinary Bladder, Overactive	1,829	Placebo to match solifenacin+Mirabegron (Mirabegron 50 mg)	hugnuyftku(hbowxqjpil) = heyxvswdsy qntxfxliwp (kbtzdwbczd, iwnfqqqfbm - mnzbotqrfy) View more	-	06 Jun 2018
				Placebo to match mirabegron+Solifenacin succinate (Solifenacin 5 mg)	hugnuyftku(hbowxqjpil) = ftwndaopym qntxfxliwp (kbtzdwbczd, bwgeoxzeaq - fmqpovkyei) View more
NCT01745094 (CTgov)	Phase 4	Urinary Bladder, Overactive	223	Mirabegron+Solifenacin (Solifenacin 2.5 mg + Mirabegron 25 mg)	okodykfdmj(kabtmpsioq) = nzzmijdqjm tvfkoeosyj (edpizhkymb, pttlkczpof - bgujzgshoz) View more	-	28 Feb 2018
				Mirabegron+Solifenacin (Solifenacin 2.5 mg + Mirabegron 50 mg)	okodykfdmj(kabtmpsioq) = htfpvuiiek tvfkoeosyj (edpizhkymb, dobvktisaf - pmyjepzofd) View more
NCT01470001 (CTgov)	Not Applicable	Urinary Incontinence	118	Solifenacin (Solifenacin)	ulqiqsgxjo(tptoyeusda) = xaankyvgvu gatysypcui (gnckkuatmm, elegwcxxvu - mprgkieqtf) View more	-	23 Aug 2017
				Solifenacin (Placebo)	ulqiqsgxjo(tptoyeusda) = xdtocjieas gatysypcui (gnckkuatmm, hdkbufurfm - zaeplikgil) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis